UroGen Pharma Ltd. Debt Securities, Available-for-sale, Unrealized Loss Position
UroGen Pharma Ltd. (URGN) had Debt Securities, Available-for-sale, Unrealized Loss Position of $19.80 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Debt and Equity Securities
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $19.80M.
- 2025-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position $45.10M.
- 2025-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $57.40M.
- 2025-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $74.20M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position |
|---|---|
| 2026-06-30 | $19.80M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $45.10M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $57.40M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $74.20M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $14.40M 10-K · filed 2025-03-10 |
| 2024-09-30 | $4.60M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $15.90M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $16.20M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $22.90M 10-K · filed 2024-03-14 |
| 2023-09-30 | $32.70M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $33.90M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $22.20M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $42.20M 10-K · filed 2023-03-24 |
| 2022-09-30 | $64.90M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $43.60M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $31.70M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $37.00M 10-K · filed 2022-03-21 |
| 2021-09-30 | $11.90M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $40.20M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-13 |
| 2020-12-31 | $0.00 10-K · filed 2021-03-18 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-09 |
| 2020-06-30 | $17.60M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $33.70M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $17.90M 10-K · filed 2020-03-02 |
| 2019-09-30 | $20.90M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $19.20M 10-Q · filed 2019-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |